Bhavesh Kevadiya

Dr. Bhavesh Kevadiya

Department of Radiology, School of Medicine, Stanford University, Palo Alto, CA 94304, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2020 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
JMJatinkumar Machhi
Jatinkumar Machhi
BKBhavesh Kevadiya
Bhavesh Kevadiya
MKMuhammad Ijaz Khan
Muhammad Ijaz Khan
JHJonathan Herskovitz
Jonathan Herskovitz
KOKatherine E. Olson
Katherine E. Olson
HGHoward Eliot Gendelman
Howard Eliot Gendelman
Emerging evidence demonstrates that adaptive immunity influences the pathobiology of neurodegenerative disorders. Misfolded aggregated self-proteins can break immune tolerance leading to the induction of autoreactive effector T cells (Teffs) with associated decreases in anti-inflammatory neuroprotective regulatory T cells (Tregs). An imbalance between Teffs and Tregs leads to microglial activation, inflammation and neuronal injury. The cascade of such a disordered immunity includes the drainage of the aggregated protein antigens into cervical lymph nodes serving to amplify effector immune responses. Both preclinical and clinical studies demonstrate transformation of this altered immunity for therapeutic gain. We posit that the signs and symptoms of common neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases, amyotrophic lateral sclerosis, and stroke can be attenuated by boosting Treg activities.Graphical

21 October 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RARobin Augustine
Robin Augustine
SDSuvarthi Das
Suvarthi Das
AHAnwarul Hasan
Anwarul Hasan
ASAbhilash S
Abhilash S
SSShaheen Salam
Shaheen Salam
BKBhavesh Kevadiya
Bhavesh Kevadiya
The aggressive outbreak of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) as COVID-19 (coronavirus disease-2019) pandemic demands rapid and simplified testing tools for its effective management. Increased mass testing and surveillance are crucial for controlling the disease spread, obtaining better pandemic statistics, and developing realistic epidemiological models. Despite the advantages of nucleic acid- and antigen-based tests such as accuracy, specificity, and non-invasive approaches of sample collection, they can only detect active infections. Antibodies (immunoglobulins) are produced by the host immune system within a few days after infection and persist in the blood for at least several weeks after infection resolution. Antibody-based tests have provided a substitute and effective method of ultra-rapid detection for multiple contagious disease outbreaks in the past, including viral diseases such as SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome). Thus, although not highly suitable for early diagnosis, antibody-based methods can be utilized to detect past infections hidden in the population, including asymptomatic ones. In an active community spread scenario of a disease that can provide a bigger window for mass detections and a practical approach for continuous surveillance. These factors encouraged researchers to investigate means of improving antibody-based rapid tests and employ them as reliable, reproducible, sensitive, specific, and economic tools for COVID-19 mass testing and surveillance. The development and integration of such immunoglobulin-based tests can transform the pandemic diagnosis by moving the same out of the clinics and laboratories into community testing sites and homes. This review discusses the principle, technology, and strategies being used in antibody-based testing at present. It also underlines the immense prospect of immunoglobulin-based testing and the efficacy of repeated planned deployment in pandemic management and post-pandemic sustainable screenings globally.

18 October 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
Tapan A. Patel, Ph.D.Tapan A. Patel, Ph.D.
Tapan A. Patel, Ph.D.
BKBhavesh Kevadiya
Bhavesh Kevadiya
NBNeha Bajwa
Neha Bajwa
Preet Amol SinghPreet Amol Singh
Preet Amol Singh
HZHong Zheng
Hong Zheng
KPKaushik P. Patel
Kaushik P. Patel
Oxidative stress is a deteriorating condition that arises due to an imbalance between the reactive oxygen species and the antioxidant system or defense of the body. The key reasons for the development of such conditions are malfunctioning of various cell organelles, such as mitochondria, endoplasmic reticulum, and Golgi complex, as well as physical and mental disturbances. The nervous system has a relatively high utilization of oxygen, thus making it particularly vulnerable to oxidative stress, which eventually leads to neuronal atrophy and death. This advances the development of neuroinflammation and neurodegeneration-associated disorders such as Alzheimer’s disease, Parkinson’s disease, epilepsy, dementia, and other memory disorders. It is imperative to treat such conditions as early as possible before they worsen and progress to irreversible damage. Oxidative damage can be negated by two mechanisms: improving the cellular defense system or providing exogenous antioxidants. Natural antioxidants can normally handle such oxidative stress, but they have limited efficacy. The valuable features of nanoparticles and/or nanomaterials, in combination with antioxidant features, offer innovative nanotheranostic tools as potential therapeutic modalities. Hence, this review aims to represent novel therapeutic approaches like utilizing nanoparticles with antioxidant properties and nanotheranostics as delivery systems for potential therapeutic applications in various neuroinflammation- and neurodegeneration-associated disease conditions.

1 December 2018 in Biomaterials
Verified
Journal Article
Closed access
BOBrendan M. Ottemann
Brendan M. Ottemann
AHAustin J. Helmink
Austin J. Helmink
WZWenting Zhang
Wenting Zhang
IMInsiya Mukadam
Insiya Mukadam
CWChristopher Woldstad
Christopher Woldstad
HGHoward Eliot Gendelman
Howard Eliot Gendelman

13 February 2018 in Bioengineering
Verified
Journal Article
Open access
PDF file
BKBhavesh Kevadiya
Bhavesh Kevadiya
MBManish Barvaliya
Manish Barvaliya
LZLu Zhang
Lu Zhang
AAAshish Anovadiya
Ashish Anovadiya
HBHarshad Brahmbhatt
Harshad Brahmbhatt
CTChandrabhanu Tripathi
Chandrabhanu Tripathi
The aim of the present study was to make a fenofibrate (FNB) nanocrystal (NC) by wet media milling, characterizations and formulates into oral strip-films (OSFs). Mechanical properties, redispersion study, and solid-state characterizations results suggested that reduction of drug crystal size at nanoscale and incorporation into OSFs does not affect the solid-state properties of the drug. In vitro dissolution kinetics showed enhanced dissolution rate was easily manipulated by changing the thickness of the OSF. In situ UV-imaging was used to monitor drug dissolution qualitatively and quantitatively in real time. Results confirm that the intrinsic dissolution rates and surface drug concentration measured with this device were in agreement with the USP-IV dissolution profiles. In vivo pharmacokinetics in rabbits showed a significant difference in the pharmacokinetics parameter (1.4 fold increase bioavailability) of FNB NC-loaded OSFs as compared to the marketed formulation “Tricor” and as-received (pristine) drug. This approach of drug nanocrystallization and incorporation into OSFs may have significant applications in cost-effective tools for bioavailability enhancement of FNB.

16 July 2019 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
BKBhavesh Kevadiya
Bhavesh Kevadiya
LCLiang Chen
Liang Chen
LZLu Zhang
Lu Zhang
MTMidhun B. Thomas
Midhun B. Thomas
Rajesh N. DaveRajesh N. Dave
Rajesh N. Dave
Hydrophobic drug nanocrystals (NCs) manufactured by particle engineering have been extensively investigated for enhanced oral bioavailability and therapeutic effectiveness. However, there are significant drawbacks, including fast dissolution of the nanocrystals in the gastric environment, leading to physicochemical instability. To solves this issue, we developed an innovative technique that involves the encapsulation of nanocrystals in composite spherical microparticles (NCSMs). Fenofibrate (FNB) NCs (FNB-NCs) manufactured by a wet stirred media milling (WSMM) technique and an ionotropic crosslinking method were used for FNB-NC encapsulation within gastroresistant NCSMs. Various solid-state methods were used for characterizing NCSMs. The pH-sensitive NCSMs showed a site-specific release pattern at alkaline pH and nearly 0% release at low pH (gastric environment). This phenomenon was confirmed by a real-time in situ UV-imaging system known as the surface dissolution imager (SDI), which was used to monitor drug release events by measuring the color intensity and concentration gradient formation. All these results proved that our NCSM approach is an innovative idea in oral drug delivery systems, as it resolves significant challenges in the intestine-specific release of hydrophobic drugs while avoiding fast dissolution or burst release.